A new regenerative-medicine hair-loss study has produced one of the more interesting early signals in androgenetic alopecia: autologous MNC-QQ cell therapy, a scalp-injection treatment made from the patient’s own peripheral blood mononuclear cells after a special quality-and-quantity culture process.
In a first-in-human, single-arm, open-label study, five men with androgenetic alopecia received subcutaneous injections of 1 × 107 autologous MNC-QQ cells into affected scalp areas. Six months later, the researchers reported significant improvements in multiple hair measures, including hair count, density, mass, thickness, and terminal hair density.
The standout number is the one serious hair-loss readers will notice immediately: terminal hair density increased 1.780-fold at 6 months. In plain English, the study reported roughly a 78% increase in terminal hair density from baseline.
That sounds huge. But the caveat is just as important as the result: this was only five patients, with no placebo group, no blinding, and no randomized control arm. It is exciting early regenerative medicine, not proof of an approved hair-loss cure.
What Is It and How Does It Work?
MNC-QQ cell therapy starts with peripheral blood mononuclear cells, also called MNCs. These are immune and progenitor-rich blood cells collected from the patient’s own blood. The “QQ” part stands for a serum-free quantity and quality control culture designed to increase the vasculogenic ability of those cells before they are injected back into tissue.
The idea is not to transplant new hair follicles. It is to improve the scalp environment around struggling follicles.
The proposed mechanism is mainly vasculogenic and regenerative:
- Blood cells are collected from the patient. Because the cells are autologous, they come from the same person receiving treatment.
- The cells are cultured under QQ conditions. The culture process is designed to enhance cell quantity and quality, especially functions linked to blood-vessel formation and tissue repair.
- The enhanced cells are injected into thinning scalp areas. In the study, the treatment was delivered by subcutaneous injection.
- The cells may release growth-supportive signals. These may improve local vascular support, follicle metabolism, tissue repair, and the dermal papilla environment.
- Miniaturized follicles may produce stronger hair. If the scalp microenvironment improves enough, follicles that are still alive may shift toward thicker terminal-hair output.
This makes MNC-QQ different from finasteride, dutasteride, minoxidil, clascoterone, microneedling, or platelet-rich plasma. It is not primarily an anti-androgen or a topical stimulant. It is closer to a cell-based regenerative approach aimed at improving the biological support system around the follicle.
The Science: Five Men, One Injection Session, Six-Month Follow-Up
The study was published in Plastic and Reconstructive Surgery and indexed on PubMed as “Uncontrolled Clinical Trial of Quality- and Quantity-Cultured Peripheral Blood Mononuclear Cell Therapy for Androgenetic Alopecia.”
The design was small and exploratory:
- Study type: single-arm, open-label clinical study.
- Participants: five men with androgenetic alopecia.
- Treatment: subcutaneous injection of 1 × 107 autologous MNC-QQ cells into affected scalp areas.
- Follow-up: 2 weeks, 1 month, 3 months, and 6 months after injection.
- Safety checks: adverse events, scalp appearance, blood examinations, and vital signs.
- Efficacy checks: photographs, Hamilton-Norwood grading, trichoscopy, and Skindex-29 quality-of-life measures.
No patient experienced an adverse effect in the reported study. Three patients improved in Hamilton-Norwood stage based on photographic evaluation, while the other two showed visible hair-growth improvement without a formal stage change.
At six months, the authors reported significant increases from baseline:
- Total hair count: 1.207-fold increase
- Hair density: 1.196-fold increase
- Hair mass: 1.427-fold increase
- Mean hair thickness: 1.212-fold increase
- Terminal hair density: 1.780-fold increase
All five patients also showed quality-of-life improvement on Skindex-29.
Why Terminal Hair Density Is the Most Interesting Signal
In androgenetic alopecia, the problem is not always that follicles disappear overnight. Many follicles miniaturize. They stay present but produce thinner, shorter, weaker hairs.
Read next
Whats the best shampoo for hair loss?
That is why terminal hair density matters. A treatment that increases terminal hair density may be helping follicles produce stronger, cosmetically visible hairs rather than only increasing tiny vellus-like fibers.
The reported 1.780-fold terminal-hair-density increase is therefore the most exciting outcome in the study. It suggests the intervention may have shifted some follicles toward more meaningful hair output.
But again, the study size matters. With only five people and no placebo group, a large fold-change can look more dramatic than it would in a larger randomized trial. The result is a strong signal for follow-up research, not a final answer.
Why Blood Flow and Vascular Biology Matter in Pattern Hair Loss
Androgenetic alopecia is usually discussed through DHT and androgen receptors, but the scalp microenvironment also matters. Follicles need oxygen, nutrients, growth factors, extracellular-matrix support, and healthy communication between dermal papilla cells, blood vessels, immune cells, and epithelial compartments.
The MNC-QQ approach is interesting because it focuses on this support system. The paper describes MNC-QQ cells as having increased vasculogenic ability. If these cells improve local vascular repair or growth-factor signaling, they may help create a scalp environment where weakened follicles can function better.
This is conceptually different from simply blocking DHT. A future best-case treatment plan might combine:
- anti-androgen control to reduce miniaturizing pressure,
- growth stimulation to push anagen activity,
- vascular/regenerative therapy to improve the follicle microenvironment,
- scalp inflammation control to reduce background stress on follicles.
MNC-QQ therapy belongs in that third category: regenerative microenvironment support.
What Makes This Different From PRP?
People will naturally compare MNC-QQ cells with platelet-rich plasma, or PRP. Both are autologous injection approaches, meaning material from the patient’s own body is processed and injected into the scalp.
But they are not the same thing. PRP is platelet-focused and relies heavily on platelet-derived growth factors. MNC-QQ is a cultured mononuclear-cell product designed to enhance vasculogenic and regenerative cell function before injection.
That does not mean MNC-QQ is automatically better. PRP has more clinical hair-loss literature behind it, although PRP protocols vary wildly. MNC-QQ currently has a much smaller human evidence base for hair loss, but the biological concept is more cell-therapy oriented.
When Will It Be Available?
MNC-QQ cell therapy for androgenetic alopecia should be viewed as investigational. This is not a standard approved hair-loss treatment that readers should expect to book at a normal clinic.
Before this can become a serious clinical option, the field needs:
- larger studies with dozens or hundreds of patients,
- randomized placebo or sham-injection controls,
- blinded hair-count assessment,
- dose-ranging studies,
- comparison with PRP, minoxidil, finasteride, dutasteride, and combination therapy,
- longer safety follow-up beyond six months,
- clear manufacturing and quality-control standards for the cell product.
The manufacturing point is critical. Cell therapies are not simple bottled products. The culture conditions, cell viability, sterility, phenotype, dose, injection technique, and regulatory oversight all matter.
How You Can Benefit From This Research Now
You cannot responsibly treat MNC-QQ cell therapy as a proven consumer option yet. But the study gives useful clues for anyone building a smarter hair-loss plan.
- Think beyond DHT alone. Androgen signaling matters, but vascular support, inflammation, fibrosis, oxidative stress, and dermal papilla health also shape follicle output.
- Watch terminal hair density, not just shedding. The most interesting signal in this study was stronger terminal-hair output.
- Be cautious with regenerative marketing. A tiny first-in-human study does not justify expensive clinic packages making guaranteed regrowth claims.
- Ask for objective measurements. Any regenerative treatment should be tracked with standardized photos, trichoscopy, hair counts, shaft diameter, and density, not just testimonials.
- Use proven foundations while the science matures. Minoxidil, finasteride or dutasteride when appropriate, anti-inflammatory scalp care, nutrition correction, and dermatologist monitoring remain the practical backbone.
The bottom line: MNC-QQ cell therapy is one of the most intriguing early regenerative hair-loss signals of 2026. A one-time autologous cell-injection protocol produced significant six-month improvements across multiple hair measures in five men, including a reported 78% terminal-hair-density increase and no adverse effects. But this is a tiny uncontrolled study. The right response is excitement plus discipline: follow the next trials, demand controlled data, and do not mistake a promising signal for a proven cure.
Sources
- Uncontrolled Clinical Trial of Quality- and Quantity-Cultured Peripheral Blood Mononuclear Cell Therapy for Androgenetic Alopecia – PubMed
- Plastic and Reconstructive Surgery article DOI record
- OpenAlex record and abstract for MNC-QQ cell therapy in androgenetic alopecia
- Juntendo University regenerative medicine publications listing